Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

New TPA Report Finds FDA Costs Soaring, Drug Rejections Rising

prnewswire.com
MRNA The article mentions Moderna in the context of the FDA refusing to examine an application for its mRNA seasonal flu vaccine, but this is presented as an issue with the FDA's process rather than a direct negative reflection on Moderna's prospects.

New TPA Report Finds FDA Costs Soaring, Drug Rejections Rising WASHINGTON, March 26, 2026 /PRNewswire/ -- Today, the Taxpayers Protection Alliance (TPA) released a report, "Blocking Breakthroughs: Delays and Denials at the FDA," highlighting the many issues with the Food and Drug Administration's (FDA's) drug approval process. The report comes amid continued controversy over the agency insisting on unrealistic and ethically-fraught criteria for approvals and walking back a bizarre decision to refuse to examine an application by Moderna for its first mRNA seasonal flu vaccine. Fortunately, FDA Center for Biologics Evaluation and Research Director Vinay Prasad—who played a key role in these decisions—will soon be leaving the agency.

Key report findings include:

Ross Marchand, Executive Director of the Taxpayers Protection Alliance, offered the following comment:

"For too long, the FDA has stood in between patients and life-saving treatments. New leaders at the helm of the Department of Health and Human Services (HHS) and FDA, such as Robert F. Kennedy Jr. and Dr. Marty Makary, have promised to make America healthier and bolster patient access to care. This report shows that is simply not happening, and millions of Americans are paying the price. Bureaucrats need to get out of the way and put patients first.

"There are plenty of steps the FDA and Congress can take to improve the drug approval process and expand access. Promising reforms include approval reciprocity with other nations, embracing a wider variety of outcomes-based data, and allowing more medications to be sold over the counter. With the right combination of changes, long-stalled drugs can finally come to market and be easily accessed by patients.

"It's long past time for FDA reform. Policymakers need to step up and do right by patients. Millions of Americans will benefit from a faster and more reliable drug approval process."

The Taxpayers Protection Alliance (TPA) is a non-profit, non-partisan organization dedicated to educating the public through the research, analysis, and dissemination of information on the government's impact on the economy.

SOURCE Taxpayers Protection Alliance